The Biology and Treatment of Atypical Ductal Hyperplasia (ADH) and Lobular Carcinoma in Situ (LCIS)

October 7, 2026

 

Live Webinar

Please make note of the activity timeframe in your Time Zone:
4:00 to 5:00pm PT | 5:00 to 6:00pm MT | 6:00 to 7:00pm CT | 7:00 to 8:00pm ET 

Atypical ductal hyperplasia (ADH) and lobular carcinoma in situ (LCIS) are benign breast disease, however, can be at high risk for breast cancer. Understanding the biology and treatment of ADH and LCIS is imperative for breast cancer prevention. These diagnoses are often viewed differently across providers because they represent elevated breast cancer risk rather than an active cancer diagnosis. As a result, practice may vary in how patients are counseled, screened and offered risk-reduction strategies.

New data and evolving recommendations continue to shape how ADH and LCIS are evaluated and managed. These conditions are complex and require clinicians to distinguish between cancer risk, cancer diagnosis, appropriate surveillance, and preventative treatment options. Education will help align practice by clarifying evidence-based approaches and correcting misinformation that may lead to unnecessary testing or missed opportunities for risk education.

Target Audience

Physicians evaluating and treating breast atypical ductal hyperplasia and lobular carcinoma in situ, and all other allied health care professionals interested in the subject matter.

Learning Objectives

  • Examine the biology of atypical ductal hyperplasia (ADH) and lobular carcinoma in situ (LCIS)     
  • Distinguish between breast cancer risk and a breast cancer diagnosis in the evaluation of ADH and LCIS.     
  • Discuss the role and benefits of drug-based prevention strategies for patients at elevated breast cancer risk.     
  • Identify appropriate screening strategies for patients with ADH and LCIS.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).

Activity summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this The Biology and Treatment of Atypical Ductal Hyperplasia (ADH) and Lobular Carcinoma in Situ (LCIS) for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
09/09/2026
Activity expires: 
10/09/2026
Event starts: 
10/07/2026 - 4:00pm PDT
Event ends: 
10/07/2026 - 5:00pm PDT
Cost:
$1.00
Add to calendar: 
City of Hope | Virtual

Live Webinar link will be provided to confirmed registrants.

 

Lawrence D. Wagman, MD, FACS
Professor, Department of Surgery
Regional Medical Director, Inland Empire and South Bay
City of Hope

 

DISCLOSURES

Presenter: Dr. Wagman has indicated that there are no relevant financial relationships with ineligible companies.

This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content. 

CME Committee/Reviewer no relevant financial relationships:  Daneng Li, MD

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this The Biology and Treatment of Atypical Ductal Hyperplasia (ADH) and Lobular Carcinoma in Situ (LCIS) for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance

Price

Cost:
$1.00
Please login or register to take this activity.

LAST DAY TO REGISTER IS Tuesday, October 6, 2026

You must be logged in to your account to complete your registration. 

Under "Registrant Type" dropdown (above), select your profession and click "Add to Cart". Follow the payment prompts. 

You will receive an email confirmation once you are registered.  

Registrant Type

Registration

Physician$0
Other Allied Health Care Provider$0
Resident/Fellow $0
*Industry/Commercial Employee Attendee$0


For questions, contact the Department of Continuing Medical Education at [email protected] or 626-218-5622 

*Industry/Commercial Employee Attendee is defined as any individual (regardless of degree) employed by a for-profit entity producing, marketing, selling, re-selling or distributing healthcare products used by or on patients, including biotech, financial, pharmaceutical, etc.